Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin plus cadonilimab versus paclitaxel in previously treated HER2-expressing advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
CTR20240110Phase 3Active
- Sponsor
- RemeGen
- Start
- Feb 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin, cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Feb 2024; status: active.
02
Drugs
disitamab vedotincadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20240110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240110.